Indirect Regulation and Equilibrium of p35 and p40 Subunits of Interleukin (IL)-12/23 by Ustekinumab in Psoriasis Treatment

BACKGROUND: Ustekinumab, a human-derived monoclonal antibody that targets the p40 subunit of interleukin (IL)-12 and IL-23, has excellent clinical efficacy and safety in treating psoriasis, with a long half-life. However, no reports have described the use of human skin/serum samples to elucidate its...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jiong, Shen, Ji-Yang, Liu, Lun-Fei, Chen, Ji-Su, Dou, Ting-Ting, Zheng, Min, Cai, Sui-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977627/
https://www.ncbi.nlm.nih.gov/pubmed/31910201
http://dx.doi.org/10.12659/MSM.920371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977627/
https://www.ncbi.nlm.nih.gov/pubmed/31910201
http://dx.doi.org/10.12659/MSM.920371

Ejemplares similares